{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:16:12Z","timestamp":1777097772556,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sosei Heptares"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The cholinergic system and M<jats:sub>1<\/jats:sub> receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M<jats:sub>1<\/jats:sub> receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia\u2019s including Alzheimer\u2019s disease (AD) and dementia with Lewy bodies (DLB). We investigated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple doses of HTL0018318 in healthy younger adults and elderly subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomised, double blind, placebo-controlled study was performed, investigating oral doses of 15\u201335\u2009mg\/day HTL0018318 or placebo in 7 cohorts of healthy younger adult (<jats:italic>n<\/jats:italic>\u2009=\u200936; 3 cohorts) and elderly (<jats:italic>n<\/jats:italic>\u2009=\u200950; 4 cohorts) subjects. Safety, tolerability and pharmacokinetic measurements were performed. Pharmacodynamics were assessed using a battery of neurocognitive tasks and electrophysiological biomarkers of synaptic and cognitive functions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HTL0018318 was generally well-tolerated in multiple doses up to 35\u2009mg\/day and were associated with mild or moderate cholinergic adverse events. There were modest increases in blood pressure and pulse rate when compared to placebo-treated subjects, with tendency for the blood pressure increase to attenuate with repeated dosing. There were no clinically significant observations or changes in blood and urine laboratory measures of safety or abnormalities in the ECGs and 24-h Holter assessments. HTL0018318 plasma exposure was dose-proportional over the range 15\u201335\u2009mg. Maximum plasma concentrations were achieved after 1\u20132\u2009h. The apparent terminal half-life of HTL0018318 was 16.1\u2009h (\u00b1 4.61) in younger adult subjects and 14.3\u2009h (\u00b1 2.78) in elderly subjects at steady state. HTL0018318 over the 10\u2009days of treatment had significant effects on tests of short-term (working) memory (<jats:italic>n<\/jats:italic>-back) and learning (Milner maze) with moderate to large effect sizes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Multiple doses of HTL0018138 showed well-characterised pharmacokinetics and were safe and generally well-tolerated in the dose range studied. Pro-cognitive effects on short-term memory and learning were demonstrated across the dose range. These data provide encouraging data in support of the development of HTL0018138 for cognitive dysfunction in AD and DLB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Netherlands Trial Register identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/5008\">NTR5781<\/jats:ext-link>. Registered on 22 March 2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00816-5","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T18:08:49Z","timestamp":1619028529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study"],"prefix":"10.1186","volume":"13","author":[{"given":"Charlotte","family":"Bakker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Liptrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen P.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Jan","family":"Doll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giles A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles","family":"Congreve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona H.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert Jan","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep J.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"issue":"2","key":"816_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar A, Singh A, Ekavali. A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195\u2013203. https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"816_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-011-0831-1","volume":"122","author":"PE Potter","year":"2011","unstructured":"Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach TG. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer\u2019s disease. Acta Neuropathol. 2011;122(1):49\u201360. https:\/\/doi.org\/10.1007\/s00401-011-0831-1.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"816_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380. https:\/\/doi.org\/10.1002\/ana.410300410.","journal-title":"Ann Neurol"},{"issue":"6","key":"816_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","volume":"62","author":"M Ingelsson","year":"2004","unstructured":"Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925\u201331. https:\/\/doi.org\/10.1212\/01.WNL.0000115115.98960.37.","journal-title":"Neurology."},{"issue":"4","key":"816_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/archneur.1993.00540040011008","volume":"50","author":"L Berg","year":"1993","unstructured":"Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer\u2019s disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50(4):349\u201358. https:\/\/doi.org\/10.1001\/archneur.1993.00540040011008.","journal-title":"Arch Neurol"},{"issue":"2\u20133","key":"816_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0022-510X(82)90155-1","volume":"56","author":"GK Wilcock","year":"1982","unstructured":"Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56(2\u20133):343\u201356. https:\/\/doi.org\/10.1016\/0022-510X(82)90155-1.","journal-title":"J Neurol Sci"},{"issue":"3","key":"816_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1006\/brcg.1995.1255","volume":"28","author":"EK Perry","year":"1995","unstructured":"Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995;28(3):240\u201358. https:\/\/doi.org\/10.1006\/brcg.1995.1255.","journal-title":"Brain Cogn"},{"issue":"6","key":"816_CR8","first-page":"557","volume":"169","author":"KL Lanctot","year":"2003","unstructured":"Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, MM LL, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis. CMAJ. 2003;169(6):557\u201364.","journal-title":"CMAJ"},{"issue":"2","key":"816_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"CC Tan","year":"2014","unstructured":"Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615\u201331. https:\/\/doi.org\/10.3233\/JAD-132690.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"816_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","volume":"32","author":"JS Buckley","year":"2015","unstructured":"Buckley JS, Salpeter SR. A risk-benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging. 2015;32(6):453\u201367. https:\/\/doi.org\/10.1007\/s40266-015-0266-9.","journal-title":"Drugs Aging"},{"issue":"5","key":"816_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7326\/0003-4819-138-5-200303040-00010","volume":"138","author":"CM Clark","year":"2003","unstructured":"Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003;138(5):400\u201310. https:\/\/doi.org\/10.7326\/0003-4819-138-5-200303040-00010.","journal-title":"Ann Intern Med"},{"issue":"12","key":"816_CR12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.drudis.2019.08.009","volume":"24","author":"D Erskine","year":"2019","unstructured":"Erskine D, Taylor JP, Bakker G, Brown AJH, Tasker T, Nathan PJ. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discov Today. 2019;24(12):2307\u201314. https:\/\/doi.org\/10.1016\/j.drudis.2019.08.009.","journal-title":"Drug Discov Today"},{"issue":"4","key":"816_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1046\/j.1471-4159.1995.64041888.x","volume":"64","author":"DD Flynn","year":"1995","unstructured":"Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer\u2019s disease. J Neurochem. 1995;64(4):1888\u201391. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.64041888.x.","journal-title":"J Neurochem"},{"issue":"2","key":"816_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/archneur.1991.00530140061018","volume":"48","author":"DR Weinberger","year":"1991","unstructured":"Weinberger DR, Gibson R, Coppola R, Jones DW, Molchan S, Sunderland T, Berman KF, Reba RC. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. Arch Neurol. 1991;48(2):169\u201376. https:\/\/doi.org\/10.1001\/archneur.1991.00530140061018.","journal-title":"Arch Neurol"},{"issue":"3","key":"816_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1124\/jpet.115.226712","volume":"355","author":"HS Lange","year":"2015","unstructured":"Lange HS, Cannon CE, Drott JT, Kuduk SD, Uslaner JM. The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys. J Pharmacol Exp Ther. 2015;355(3):442\u201350. https:\/\/doi.org\/10.1124\/jpet.115.226712.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"816_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1017\/S1461145712000752","volume":"16","author":"PJ Nathan","year":"2013","unstructured":"Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013;16(4):721\u201331. https:\/\/doi.org\/10.1017\/S1461145712000752.","journal-title":"Int J Neuropsychopharmacol"},{"key":"816_CR17","doi-asserted-by":"publisher","unstructured":"Watt ML, Schober DA, Hitchcock S, Liu B, Chesterfield AK, McKinzie D, Felder CC. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. J Pharmacol Exp Ther. 2011;338(2):622\u201332. https:\/\/doi.org\/10.1124\/jpet.111.182063.","DOI":"10.1124\/jpet.111.182063"},{"issue":"4","key":"816_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0091-3057(99)00037-4","volume":"63","author":"AC Ruske","year":"1999","unstructured":"Ruske AC, White KG. Facilitation of memory performance by a novel muscarinic agonist in young and old rats. Pharmacol Biochem Behav. 1999;63(4):663\u20137. https:\/\/doi.org\/10.1016\/S0091-3057(99)00037-4.","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"816_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1101\/lm.043133.116","volume":"23","author":"K Leaderbrand","year":"2016","unstructured":"Leaderbrand K, Chen HJ, Corcoran KA, Guedea AL, Jovasevic V, Wess J, et al. Muscarinic acetylcholine receptors act in synergy to facilitate learning and memory. Learn Mem. 2016;23(11):631\u20138.","journal-title":"Learn Mem"},{"key":"816_CR20","doi-asserted-by":"publisher","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465\u201373. https:\/\/doi.org\/10.1001\/archneur.1997.00550160091022.","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"816_CR21","doi-asserted-by":"crossref","unstructured":"Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, et al. First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias. Br J Clin Pharmacol. 2020.","DOI":"10.1111\/bcp.14710"},{"key":"816_CR22","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"816_CR23","doi-asserted-by":"publisher","unstructured":"Baakman AC, T Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, et al. First in human study with a prodrug of galantamine: improved benefit-risk ratio? Alzheimer\u2019s Dementia 2016;2(1):13\u201322, doi: https:\/\/doi.org\/10.1016\/j.trci.2015.12.003.","DOI":"10.1016\/j.trci.2015.12.003"},{"issue":"5","key":"816_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bcp.13507","volume":"84","author":"R Alvarez-Jimenez","year":"2018","unstructured":"Alvarez-Jimenez R, Hart EP, Prins S, de Kam M, van Gerven JMA, Cohen AF, Groeneveld GJ. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: cognitive and (electro) physiological responses. Br J Clin Pharmacol. 2018;84(5):888\u201399. https:\/\/doi.org\/10.1111\/bcp.13507.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"816_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp.73.6.665","volume":"73","author":"SA Rombouts","year":"2002","unstructured":"Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):665\u201371. https:\/\/doi.org\/10.1136\/jnnp.73.6.665.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"816_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.clinph.2012.09.017","volume":"124","author":"C Babiloni","year":"2013","unstructured":"Babiloni C, Del Percio C, Bordet R, Bourriez JL, Bentivoglio M, Payoux P, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer\u2019s disease patients. Clin Neurophysiol. 2013;124(5):837\u201350. https:\/\/doi.org\/10.1016\/j.clinph.2012.09.017.","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"816_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-2007-1014282","volume":"27","author":"T Dierks","year":"1994","unstructured":"Dierks T, Frolich L, Ihl R, Maurer K. Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry. 1994;27(2):72\u20134. https:\/\/doi.org\/10.1055\/s-2007-1014282.","journal-title":"Pharmacopsychiatry."},{"issue":"3","key":"816_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party. Drug Information J. 1995;29(3):1039\u201348. https:\/\/doi.org\/10.1177\/009286159502900324.","journal-title":"Drug Information J"},{"issue":"1","key":"816_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.301.1.129","volume":"301","author":"SN Hardouin","year":"2002","unstructured":"Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, Nathanson NM. Altered cardiovascular responses in mice lacking the M (1) muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2002;301(1):129\u201337. https:\/\/doi.org\/10.1124\/jpet.301.1.129.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"816_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1523\/JNEUROSCI.1305-19.2019","volume":"40","author":"M Sarter","year":"2020","unstructured":"Sarter M, Lustig C. Forebrain cholinergic signaling: wired and phasic, not tonic, and causing behavior. J Neurosci. 2020;40(4):712\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.1305-19.2019.","journal-title":"J Neurosci"},{"issue":"12","key":"816_CR31","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1162\/jocn.2008.21172","volume":"21","author":"A Tsuchida","year":"2009","unstructured":"Tsuchida A, Fellows LK. Lesion evidence that two distinct regions within prefrontal cortex are critical for n-back performance in humans. J Cogn Neurosci. 2009;21(12):2263\u201375. https:\/\/doi.org\/10.1162\/jocn.2008.21172.","journal-title":"J Cogn Neurosci"},{"key":"816_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuroimage.2019.03.074","volume":"196","author":"ZA Yaple","year":"2019","unstructured":"Yaple ZA, Stevens WD, Arsalidou M. Meta-analyses of the n-back working memory task: fMRI evidence of age-related changes in prefrontal cortex involvement across the adult lifespan. NeuroImage. 2019;196:16\u201331. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.03.074.","journal-title":"NeuroImage."},{"issue":"4","key":"816_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0028-3932(65)90005-9","volume":"3","author":"B Milner","year":"1965","unstructured":"Milner B. Visually-guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions. Neuropsychologia. 1965;3(4):317\u201338. https:\/\/doi.org\/10.1016\/0028-3932(65)90005-9.","journal-title":"Neuropsychologia."},{"issue":"5\u20136","key":"816_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","volume":"52","author":"AI Levey","year":"1993","unstructured":"Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993;52(5\u20136):441\u20138. https:\/\/doi.org\/10.1016\/0024-3205(93)90300-R.","journal-title":"Life Sci"},{"issue":"1","key":"816_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/cercor\/bhv227","volume":"26","author":"SH Dennis","year":"2016","unstructured":"Dennis SH, Pasqui F, Colvin EM, Sanger H, Mogg AJ, Felder CC, et al. Activation of muscarinic M1 acetylcholine receptors induces long-term potentiation in the hippocampus. Cereb Cortex. 2016;26(1):414\u201326.","journal-title":"Cereb Cortex"},{"issue":"5","key":"816_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","volume":"49","author":"A Caccamo","year":"2006","unstructured":"Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2006.01.020.","journal-title":"Neuron."},{"issue":"4","key":"816_CR37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","volume":"12","author":"AE Veroff","year":"1998","unstructured":"Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12(4):304\u201312. https:\/\/doi.org\/10.1097\/00002093-199812000-00010.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"816_CR38","first-page":"173","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2018;4:173\u201381.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"8","key":"816_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/j.1552-4604.1995.tb04123.x","volume":"35","author":"JJ Sramek","year":"1995","unstructured":"Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR. The safety and tolerance of xanomeline tartrate in patients with Alzheimer\u2019s disease. J Clin Pharmacol. 1995;35(8):800\u20136. https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04123.x.","journal-title":"J Clin Pharmacol"},{"issue":"22\u201323","key":"816_CR40","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/S0024-3205(01)01057-8","volume":"68","author":"M Wienrich","year":"2001","unstructured":"Wienrich M, Meier D, Ensinger HA, Gaida W, Raschig A, Walland A, Hammer R. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci. 2001;68(22\u201323):2593\u2013600. https:\/\/doi.org\/10.1016\/S0024-3205(01)01057-8.","journal-title":"Life Sci"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T18:09:38Z","timestamp":1619028578000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00816-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the medical ethics review board of the foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO, Assen, The Netherlands).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT, JL, GB, AB, MC, MW, FM and PN all are currently, or have been, paid employees of SH and have owned stock in the company; DC is a paid independent consultant for SH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}